查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1672040

全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場研究報告 - 產業分析、規模、佔有率、成長、趨勢和預測 2025 年至 2033 年

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Research Report- Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
出版日期: | 出版商: Value Market Research | 英文 131 Pages | 商品交期: 最快1-2個工作天內

價格

全球陣發性睡眠性血紅蛋白尿 (PNH) 治療市場規模預計將從 2024 年的 48.8 億美元成長到 2033 年的 133.1 億美元，在 2026 年至 2033 年的預測期內呈現 11.77% 的強勁年複合成長率(CAGR)。

陣發性睡眠性血紅蛋白尿症 (PNH) 治療市場正在經歷重大進步，這得益於對該疾病的深入了解和針對性治療方法的發展。 PNH 是一種罕見且使人衰弱的血液疾病，其特徵是紅血球的破壞，由於其複雜性，治療一直面臨挑戰。然而，補體抑制劑等單株抗體療法的最新突破徹底改變了這種疾病的治療方式，為患者提供了更好的治療效果和生活品質。

PNH 盛行率的不斷上升，加上醫療專業人員認知的不斷提高，推動了對有效治療方案的需求。隨著診斷技術的進步，越來越多的患者得到識別和治療，進一步推動市場成長。此外，正在進行的臨床試驗和研究計劃專注於探索聯合療法和新治療方式，並有望擴大 PNH 的治療前景。這種對創新的關注至關重要，因為它解決了那些對現有療法可能沒有充分反應的患者的未滿足需求。

此外，對個人化醫療的日益重視正在影響 PNH 治療市場。根據個別患者概況和基因標記制定治療計劃變得越來越可行，從而可以實現更有效、更有針對性的干涉。製藥公司和研究機構之間的合作正在促進旨在提高療效和減少副作用的下一代療法的發展。總之，PNH 治療市場將實現強勁成長，其特點是創新、認知的提高以及致力於改善這一充滿挑戰的治療領域的患者治療效果。

我們的報告經過精心製作，為客戶提供有關各個行業和市場的全面且可操作的見解。每份報告都包含幾個關鍵部分，以確保徹底了解市場格局：

市場概覽：市場的詳細介紹，包括定義、分類和行業現狀概述。

市場動態：深入分析影響市場成長的關鍵促進因素、限制因素、機會與挑戰。本節探討技術進步、監管變化和新興趨勢等因素。

細分分析：根據產品類型、應用、最終用戶和地理位置等標準將市場細分為不同的細分市場。該分析強調了每個部分的表現和潛力。

競爭格局：對主要市場參與者的全面評估，包括其市場佔有率、產品組合、策略舉措和財務表現。本節深入介紹領先公司的競爭動態和關鍵策略。

市場預測：根據歷史資料和當前市場狀況，預測特定時期內的市場規模和成長趨勢。這包括定量分析和圖形表示來說明未來的市場軌跡。

區域分析：評估不同地理區域的市場表現，確定關鍵市場和區域趨勢。這有助於了解區域市場動態和機會。

新興趨勢與機會：識別當前和新興的市場趨勢、技術創新和潛在投資領域。本節提供未來市場發展和成長前景的見解。

報告涵蓋的細分

按治療類型

  • 補體抑制劑
  • 鐵療法
  • 免疫抑制藥物
  • 骨髓移植
  • 其他治療類型

依給藥途徑

  • 口服
  • 腸外

按年齡層

  • 兒科
  • 成人

按最終用途

  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他最終用戶
  • 公司簡介
  • 安進公司
  • Apellis 製藥公司
  • 阿斯特捷利康公司
  • 兒童國家醫院
  • F.霍夫曼-羅氏有限公司
  • 紀念斯隆凱特琳癌症中心
  • 諾華公司
  • 輝瑞公司
  • 再生元製藥公司（Regeneron Pharmaceuticals Inc.）
  • 梯瓦製藥工業股份有限公司
  • 加州大學洛杉磯分校健康
  • 羅徹斯特大學醫學中心
  • 以上清單可以自訂。

目錄

第 1 章：前言

  • 報告描述
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究流程
    • 市場研究方法

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：陣發性睡眠性血紅素尿症 (PNH) 治療產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業趨勢
  • 波特五力分析
  • 市場吸引力分析
    • 依治療類型進行市場吸引力分析
    • 按給藥途徑進行的市場吸引力分析
    • 按年齡分析市場吸引力
    • 按最終用途進行的市場吸引力分析
    • 市場吸引力分析：按地區

第4章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料製造商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：依治療類型

  • 按治療類型概述
  • 按治療類型進行的歷史和預測數據分析
  • 補體抑制劑
  • 鐵療法
  • 免疫抑制藥物
  • 骨髓移植
  • 其他

第 6 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：按給藥途徑

  • 依給藥途徑概述
  • 按給藥途徑進行的歷史和預測數據分析
  • 口服
  • 腸外

第 7 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：按年齡層

  • 按年齡層別概覽
  • 按年齡層別進行的歷史和預測資料分析
  • 兒科
  • 成人

第 8 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：依照最終用途

  • 按最終用途概述
  • 按最終用途進行的歷史和預測數據分析
  • 醫院
  • 專科診所
  • 家庭護理設置
  • 其他

第 9 章：全球陣發性睡眠性血紅素尿症 (PNH) 治療市場分析：按地區分類

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概述、歷史和預測數據銷售分析
    • 北美各細分市場銷售分析
    • 北美各國銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 歐洲各細分市場銷售分析
    • 歐洲各國銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概述、歷史和預測數據銷售分析
    • 亞太地區分部銷售分析
    • 亞太地區國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 拉丁美洲各細分市場銷售分析
    • 拉丁美洲各國銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概述、歷史和預測數據銷售分析
    • 中東和非洲分部銷售分析
    • 中東和非洲國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東和非洲其他地區銷售分析

第 10 章：陣發性睡眠性血紅素尿症 (PNH) 治療公司的競爭格局

  • 陣發性睡眠性血紅素尿症（PNH）治療市場競爭
  • 夥伴關係/合作/協議
  • 合併與收購
  • 新產品發布
  • 其他進展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Amgen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Apellis Pharmaceuticals Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • AstraZeneca Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Children'S National Hospital
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • F. Hoffmann-La Roche Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Memorial Sloan Kettering Cancer Center
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novartis AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Regeneron Pharmaceuticals Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Teva Pharmaceuticals Industries Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • UCLA Health
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • University Of Rochester Medical Center
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

注意 - 在公司簡介中，財務細節和最新發展取決於可用性，對於私人公司，可能不予涵蓋

Product Code: VMR11210464

Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size is anticipated to grow from USD 4.88 Billion in 2024 to USD 13.31 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 11.77% during the forecast period of 2026 to 2033.

The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.

The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.

Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Treatment Type

  • Complement Inhibitors
  • Iron Therapy
  • Immunosuppressant Drugs
  • Bone Marrow Transplantation
  • Other Treatment Types

By Route Of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adult

By End-use

  • Hospitals
  • Specialty clinics
  • Homecare settings
  • Other end-users
  • COMPANIES PROFILED
  • Amgen Inc.
  • Apellis Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Children's National Hospital
  • F. Hoffmann-La Roche Ltd.
  • Memorial Sloan Kettering Cancer Center
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • UCLA Health
  • University of Rochester Medical Center
  • The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porters Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Treatment Type
    • 3.7.2 Market Attractiveness Analysis By Route of Administration
    • 3.7.3 Market Attractiveness Analysis By Age Group
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT TYPE

  • 5.1. Overview By Treatment Type
  • 5.2. Historical and Forecast Data Analysis By Treatment Type
  • 5.3. Complement Inhibitors Historic and Forecast Sales By Regions
  • 5.4. Iron Therapy Historic and Forecast Sales By Regions
  • 5.5. Immunosuppressant Drugs Historic and Forecast Sales By Regions
  • 5.6. Bone Marrow Transplantation Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 6.1. Overview By Route of Administration
  • 6.2. Historical and Forecast Data Analysis By Route of Administration
  • 6.3. Oral Historic and Forecast Sales By Regions
  • 6.4. Parenteral Historic and Forecast Sales By Regions

7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY AGE GROUP

  • 7.1. Overview By Age Group
  • 7.2. Historical and Forecast Data Analysis By Age Group
  • 7.3. Pediatric Historic and Forecast Sales By Regions
  • 7.4. Adult Historic and Forecast Sales By Regions

8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-use
  • 8.2. Historical and Forecast Data Analysis By End-use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty clinics Historic and Forecast Sales By Regions
  • 8.5. Homecare settings Historic and Forecast Sales By Regions
  • 8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES

  • 10.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Amgen Inc.
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Apellis Pharmaceuticals Inc.
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. AstraZeneca Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Children'S National Hospital
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. F. Hoffmann-La Roche Ltd.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Memorial Sloan Kettering Cancer Center
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Novartis AG
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Pfizer Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Regeneron Pharmaceuticals Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Teva Pharmaceuticals Industries Ltd.
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. UCLA Health
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. University Of Rochester Medical Center
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty clinics Market Sales By Geography (USD MN)
  • Homecare settings Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Report
  • Market Research Process
  • Market Research Methodology
  • Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Treatment Type
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By Age Group
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Treatment Type (USD MN)
  • Complement Inhibitors Market Sales By Geography (USD MN)
  • Iron Therapy Market Sales By Geography (USD MN)
  • Immunosuppressant Drugs Market Sales By Geography (USD MN)
  • Bone Marrow Transplantation Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Parenteral Market Sales By Geography (USD MN)
  • Global Market Analysis By Age Group (USD MN)
  • Pediatric Market Sales By Geography (USD MN)
  • Adult Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty clinics Market Sales By Geography (USD MN)
  • Homecare settings Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis
  • Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.